文献速递慢性肾脏病遗传性与小管间质肾病

托伐普坦治疗常染色体显性多囊肾病关键试验中他汀使用的事后分析

A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-04-02

该事后分析基于TEMPO 3:4和REPRISE两项随机对照试验,共2815例ADPKD患者,其中597例(21.2%)使用他汀。结果显示托伐普坦联合他汀未显著增加他汀相关不良事件或肝酶升高风险,支持两者联用的安全性。

要点

  • 托伐普坦联合他汀未显著增加肌痛、腹痛等他汀相关不良事件。
  • 联合组与安慰剂组他汀使用参数(持续时间、剂量变化等)无差异。
  • 肝酶超过3倍正常上限的发生率两组差异无统计学意义。

核心结论

  • 在临床试验中,托伐普坦与他汀联用是安全的。

研究设计与样本

  • TEMPO 3:4和REPRISE两项随机对照试验的事后分析,共纳入2815例早期至晚期ADPKD患者,托伐普坦组1644例,安慰剂组1171例,治疗3年(TEMPO 3:4)和1年(REPRISE)。

主要发现

  • 597例(21.2%)受试者使用他汀,其中托伐普坦组332例(20.2%),安慰剂组265例(22.6%)。
  • 托伐普坦组与安慰剂组他汀使用参数(持续时间、剂量变化、他汀更换、永久停药)无差异。
  • TEMPO 3:4中,托伐普坦+他汀组与安慰剂+他汀组肌痛频率分别为5.4%和7.8%(差值-2.4%,95%CI -11.2%至6.4%),腹痛分别为9.3%和7.8%(差值1.5%,95%CI -7.9%至10.9%)。
  • 排除合用别嘌醇者后,托伐普坦+他汀组与安慰剂+他汀组丙氨酸转氨酶或天冬氨酸转氨酶>3倍正常上限的频率分别为3.6%和2.3%(差值1.4%,95%CI -2.0%至4.7%)。

临床怎么用

  • 临床实践中,ADPKD患者使用托伐普坦时可根据需要联用他汀,无需仅因药物相互作用担忧而避免。

局限性

  • 本研究为事后分析,他汀使用不受限制,非随机分配,可能存在混杂偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Tolvaptan is approved to slow kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. Because in vitro studies indicated that the tolvaptan oxobutyric acid metabolite inhibits organic anion-transporting polypeptide (OATP)1B1 and OATP1B3, United States prescribing information advises avoiding concurrent use with OATP1B1/1B3 substrates, including hepatic hydroxymethyl glutaryl-CoA reductase inhibitors (statins). This post hoc analysis of the pivotal phase 3 tolvaptan trials (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes [TEMPO] 3:4 trial [NCT00428948] and Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD [REPRISE] trial [NCT02160145]) examined the safety of concurrent tolvaptan/statin use. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The trials randomized a combined total of 2815 subjects with early- to late-stage ADPKD to tolvaptan (n=1644) or placebo (n=1171) for 3 years (TEMPO 3:4) and 1 year (REPRISE). Statin use was unrestricted, and 597 subjects (21.2% overall; 332 [20.2%] tolvaptan, 265 [22.6%] placebo) received statins. Statin use (duration, dose change, statin change, permanent discontinuation), incidences of statin-related adverse events, and hepatic transaminase elevations were determined for subjects who received tolvaptan+statin, placebo+statin, tolvaptan alone, and placebo alone. RESULTS: No differences in statin use parameters between tolvaptan- and placebo-treated subjects were observed. No statistically significant increases in commonly reported statin-related adverse events (e.g., musculoskeletal disorders, gastrointestinal symptoms) were seen between subjects receiving tolvaptan+statin and placebo+statin. For example, in TEMPO 3:4, frequencies were 5.4% and 7.8%, respectively, for myalgia (difference -2.4%; 95% confidence interval, -11.2% to 6.4%) and 9.3% and 7.8%, respectively, for abdominal pain (difference 1.5%; -7.9% to 10.9%). In an analysis that excluded participants concurrently using allopurinol, the frequency of alanine transaminase or aspartate transaminase >3× upper limit of normal in the pooled study populations was 3.6% for the tolvaptan+statin group and 2.3% for the placebo+statin group (difference 1.4%; -2.0% to 4.7%). CONCLUSIONS: Tolvaptan has been used safely in combination with statins in clinical trials. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_04_06_CJN.08170719.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Shoaf SE, Ouyang J, Sergeyeva O, et al. A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials. Clin J Am Soc Nephrol. 2020. PMID: 32241780. doi:10.2215/CJN.08170719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。